ArticleJournal of the American Heart Association2026
Longitudinal Changes in Frailty and Major Adverse Cardiovascular Events in Patients With Coronary Heart Disease.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrailty is common among patients with coronary heart disease (CHD). This study aimed to examine both baseline frailty and its longitudinal changes in relation to the risk of major adverse cardiovascular events (MACEs) in patients with CHD.
methodsData were sourced from the ARIC (Atherosclerosis Risk in Communities) study. Frailty status was assessed using a modified Fried frailty phenotype at 2 consecutive surveys. The outcome was MACEs, defined as a composite of recurrent CHD, incident heart failure, stroke, or cardiovascular death. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs.
resultsIn baseline frailty analyses, 1793 patients with CHD were included. Compared with robust patients, prefrail and frail patients had a higher risk of MACEs (HR, 1.24 [95% CI, 1.08-1.42] for prefrail; and HR, 1.75 [95% CI, 1.43-2.15] for frail). In frailty transition analyses, 862 patients with CHD were included. Patients who progressed from robust to prefrail/frail status had a higher MACE risk (HR, 1.43 [95% CI, 1.07-1.91]) compared with those who remained robust. Similarly, progression from prefrail to frail status was associated with an increased risk of MACEs (HR, 2.30 [95% CI, 1.62-3.27]) compared with stable prefrailty. Conversely, recovery from prefrail to robust status was related to a decreased MACE risk (HR, 0.62 [95% CI, 0.40-0.96]).
conclusionsBoth baseline frailty and its temporal changes were associated with the risk of MACEs among patients with CHD, highlighting the clinical value of monitoring and intervening for frailty in CHD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.